204001(204001交易规则是什么)

“学科前瞻”栏目又和大家见面204001了204001，ESI于2022年11月10日进行了更新，涵盖了2012年1月1日至2022年8月31日共计10年8个月的论文数据。本次数据更新后，东北大学临床医学学科首次进入了ESI全球前1%，成为东北大学第 七个入选ESI全球前1%的学科。目前，东北大学进入ESI全球前1%的学科分别是材料科学、工程学、化学、计算机科学、地球科学、环境/生态学以及临床医学。

本期介绍 ESI临床医学领域排名前五的高被引论文、热点论文及其出版物相关信息，ESI 22个学科分类具体详见文末介绍。

高被引论文

高被引论文（Highly Cited Paper）：是指最近十年间各研究领域中被引频次排名位于全球前1%的论文。

ESI临床医学高被引论文Top5

根据2022年11月ESI发布的数据进行统计分析，对临床医学领域高水平论文按照被引频次进行排序得到排名前五的论文信息及其来源出版物信息。

1

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

作者：Bray, F (Bray, Freddie); Ferlay, J (Ferlay, Jacques); Soerjomataram, I (Soerjomataram, Isabelle); Siegel, RL (Siegel, Rebecca L.); Torre, LA (Torre, Lindsey A.); Jemal, A (Jemal, Ahmedin)

来源出版物：CA-A CANCER JOURNAL FOR CLINICIANS 卷: 68 期: 6 页: 394-424 DOI: 10.3322/caac.21492 出版年: NOV-DEC 2018

摘要：This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. (c) 2018 American Cancer Society

来源出版物：CA-A CANCER JOURNAL FOR CLINICIANS

出版商：WILEY

ISSN: 0007-9235

影响因子（2021）：286.130

收录情况：SCIE

2

Cancer Statistics, 2015

作者：Siegel, RL (Siegel, Rebecca L.); Miller, KD (Miller, Kimberly D.); Jemal, A (Jemal, Ahmedin)

来源出版物：CA-A CANCER JOURNAL FOR CLINICIANS 卷: 65 期: 1 页: 5-29 DOI: 10.3322/caac.21254 出版年: JAN-FEB 2015

摘要：Each year the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries. Mortality data were collected by the National Center for Health Statistics. A total of 1,658,370 new cancer cases and 589,430 cancer deaths are projected to occur in the United States in 2015. During the most recent 5 years for which there are data (2007-2011), delay-adjusted cancer incidence rates (13 oldest SEER registries) declined by 1.8% per year in men and were stable in women, while cancer death rates nationwide decreased by 1.8% per year in men and by 1.4% per year in women. The overall cancer death rate decreased from 215.1 (per 100,000 population) in 1991 to 168.7 in 2011, a total relative decline of 22%. However, the magnitude of the decline varied by state, and was generally lowest in the South (approximate to 15%) and highest in the Northeast (20%). For example, there were declines of 25% to 30% in Maryland, New Jersey, Massachusetts, New York, and Delaware, which collectively averted 29,000 cancer deaths in 2011 as a result of this progress. Further gains can be accelerated by applying existing cancer control knowledge across all segments of the population. CA Cancer J Clin 2015;65:5-29. (c) 2015 American Cancer Society.

来源出版物：CA-A CANCER JOURNAL FOR CLINICIANS

出版商：WILEY

ISSN: 0007-9235

影响因子（2021）：286.130

收录情况：SCIE

3

Cancer Statistics, 2014

作者：Siegel, R (Siegel, Rebecca); Ma, JM (Ma, Jiemin); Zou, ZH (Zou, Zhaohui); Jemal, A (Jemal, Ahmedin)

来源出版物：CA-A CANCER JOURNAL FOR CLINICIANS 卷: 64 期: 1 页: 9-29 DOI: 10.3322/caac.21208 出版年: JAN 2014

摘要：Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data were collected by the National Center for Health Statistics. A total of 1,665,540 new cancer cases and 585,720 cancer deaths are projected to occur in the United States in 2014. During the most recent 5 years for which there are data (2006-2010), delay-adjusted cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.4% per year in women. The combined cancer death rate (deaths per 100,000 population) has been continuously declining for 2 decades, from a peak of 215.1 in 1991 to 171.8 in 2010. This 20% decline translates to the avoidance of approximately 1,340,400 cancer deaths (952,700 among men and 387,700 among women) during this time period. The magnitude of the decline in cancer death rates from 1991 to 2010 varies substantially by age, race, and sex, ranging from no decline among white women aged 80 years and older to a 55% decline among black men aged 40 years to 49 years. Notably, black men experienced the largest drop within every 10-year age group. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population. CA Cancer J Clin 2014;64:9-29. ((c)) 2014 American Cancer Society, Inc.

来源出版物：CA-A CANCER JOURNAL FOR CLINICIANS

出版商：WILEY

ISSN: 0007-9235

影响因子（2021）：286.130

收录情况：SCIE

4

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

作者：Ferlay, J (Ferlay, Jacques); Soerjomataram, I (Soerjomataram, Isabelle); Dikshit, R (Dikshit, Rajesh); Eser, S (Eser, Sultan); Mathers, C (Mathers, Colin); Rebelo, M (Rebelo, Marise); Parkin, DM (Parkin, Donald Maxwell); Forman, D (Forman, David); Bray, F (Bray, Freddie)

来源出版物：INTERNATIONAL JOURNAL OF CANCER 卷: 136 期: 5 页: E359-E386 DOI: 10.1002/ijc.29210 出版年: MAR 1 2015

摘要：

Estimates of the worldwide incidence and mortality from 27 major cancers and for all cancers combined for 2012 are now available in the GLOBOCAN series of the International Agency for Research on Cancer. We review the sources and methods used in compiling the national cancer incidence and mortality estimates, and briefly describe the key results by cancer site and in 20 large areas of the world. Overall, there were 14.1 million new cases and 8.2 million deaths in 2012. The most commonly diagnosed cancers were lung (1.82 million), breast (1.67 million), and colorectal (1.36 million); the most common causes of cancer death were lung cancer (1.6 million deaths), liver cancer (745,000 deaths), and stomach cancer (723,000 deaths).

What's new? In this report, we present the most recent cancer incidence and mortality statistics (for 2012) for the major cancers in 20 regions of the world. Details of the data sources and methods used in GLOBOCAN to compile the estimates at the national level are provided, and we introduce a novel alphanumeric scoring system to give a broad indication of the robustness of the estimation within each country. A global snapshot of the patterns by cancer site brings focus to the need for regional prioritisation of cancer control efforts, as well as the ongoing efforts to improve the limited surveillance systems in many low and middle income countries.

来源出版物：INTERNATIONAL JOURNAL OF CANCER

出版商：WILEY

ISSN: 0020-7136

影响因子（2021）：7.316

收录情况：SCIE

馆藏链接：

5

Global Cancer Statistics, 2012

作者：Torre, LA (Torre, Lindsey A.); Bray, F (Bray, Freddie); Siegel, RL (Siegel, Rebecca L.); Ferlay, J (Ferlay, Jacques); Lortet-Tieulent, J (Lortet-Tieulent, Joannie); Jemal, A (Jemal, Ahmedin)

来源出版物：CA-A CANCER JOURNAL FOR CLINICIANS 卷: 65 期: 2 页: 87-108 DOI: 10.3322/caac.21262 出版年: MAR-APR 2015

摘要：Cancer constitutes an enormous burden on society in more and less economically developed countries alike. The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development. Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide. Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide. Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries. Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males. In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death. Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries. This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment. Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer). A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests. CA Cancer J Clin 2015;65: 87-108. (c) 2015 American Cancer Society.

来源出版物：CA-A CANCER JOURNAL FOR CLINICIANS

出版商：WILEY

ISSN: 0007-9235

影响因子（2021）：286.130

收录情况：SCIE

热点

论文

热点论文（Hot Paper）：是指最近两年内各研究领域中被引频次在最近两个月内排名位于全球前0.1%的论文。

ESI热点论文Top5

根据2022年11月ESI发布的数据进行统计分析，对临床医学领域热点论文按照被引频次进行排序得到排名前五的论文信息及其来源出版物信息。

1

Cancer statistics, 2022

作者：Siegel, RL (Siegel, Rebecca L.); Miller, KD (Miller, Kimberly D.); Fuchs, HE (Fuchs, Hannah E.); Jemal, A (Jemal, Ahmedin)

来源出版物：CA-A CANCER JOURNAL FOR CLINICIANS 卷: 72 期: 1 页: 7-33 DOI: 10.3322/caac.21708 提前访问日期: JAN 2022 出版年: JAN 2022

摘要：Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. Incidence data (through 2018) were collected by the Surveillance, Epidemiology, and End Results program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2019) were collected by the National Center for Health Statistics. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. Incidence during 2014 through 2018 continued a slow increase for female breast cancer (by 0.5% annually) and remained stable for prostate cancer, despite a 4% to 6% annual increase for advanced disease since 2011. Consequently, the proportion of prostate cancer diagnosed at a distant stage increased from 3.9% to 8.2% over the past decade. In contrast, lung cancer incidence continued to decline steeply for advanced disease while rates for localized-stage increased suddenly by 4.5% annually, contributing to gains both in the proportion of localized-stage diagnoses (from 17% in 2004 to 28% in 2018) and 3-year relative survival (from 21% to 31%). Mortality patterns reflect incidence trends, with declines accelerating for lung cancer, slowing for breast cancer, and stabilizing for prostate cancer. In summary, progress has stagnated for breast and prostate cancers but strengthened for lung cancer, coinciding with changes in medical practice related to cancer screening and/or treatment. More targeted cancer control interventions and investment in improved early detection and treatment would facilitate reductions in cancer mortality.

来源出版物：CA-A CANCER JOURNAL FOR CLINICIANS

出版商：WILEY

ISSN: 0007-9235

影响因子（2021）：286.130

收录情况：SCIE

2

Cancer Statistics, 2021

作者：Siegel, RL (Siegel, Rebecca L.); Miller, KD (Miller, Kimberly D.); Fuchs, HE (Fuchs, Hannah E.); Jemal, A (Jemal, Ahmedin)

来源出版物：CA-A CANCER JOURNAL FOR CLINICIANS 卷: 71 期: 1 页: 7-33 DOI: 10.3322/caac.21654 提前访问日期: JAN 2021 出版年: JAN 2021

摘要：Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.

来源出版物：CA-A CANCER JOURNAL FOR CLINICIANS

出版商：WILEY

ISSN: 0007-9235

影响因子（2021）：286.130

收录情况：SCIE

3

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

作者：Sung, H (Sung, Hyuna); Ferlay, J (Ferlay, Jacques); Siegel, RL (Siegel, Rebecca L.); Laversanne, M (Laversanne, Mathieu); Soerjomataram, I (Soerjomataram, Isabelle); Jemal, A (Jemal, Ahmedin); Bray, F (Bray, Freddie)

来源出版物：CA-A CANCER JOURNAL FOR CLINICIANS 卷: 71 期: 3 页: 209-249 DOI: 10.3322/caac.21660 提前访问日期: FEB 2021 出版年: MAY 2021

摘要：This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.

来源出版物：CA-A CANCER JOURNAL FOR CLINICIANS

出版商：WILEY

ISSN: 0007-9235

影响因子（2021）：286.130

收录情况：SCIE

4

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

作者：Polack, FP (Polack, Fernando P.); Thomas, SJ (Thomas, Stephen J.); Kitchin, N (Kitchin, Nicholas); Absalon, J (Absalon, Judith); Gurtman, A (Gurtman, Alejandra); Lockhart, S (Lockhart, Stephen); Perez, JL (Perez, John L.); Marc, GP (Perez Marc, Gonzalo); Moreira, ED (Moreira, Edson D.); Zerbini, C (Zerbini, Cristiano); Bailey, R (Bailey, Ruth); Swanson, KA (Swanson, Kena A.); Roychoudhury, S (Roychoudhury, Satrajit); Koury, K (Koury, Kenneth); Li, P (Li, Ping); Kalina, WV (Kalina, Warren V.); Cooper, D (Cooper, David); Frenck, RW (Frenck, Robert W., Jr.); Hammitt, LL (Hammitt, Laura L.); Tureci, O (Tureci, Ozlem); Nell, H (Nell, Haylene); Schaefer, A (Schaefer, Axel); Unal, S (Unal, Serhat); Tresnan, DB (Tresnan, Dina B.); Mather, S (Mather, Susan); Dormitzer, PR (Dormitzer, Philip R.); Sahin, U (Sahin, Ugur); Jansen, KU (Jansen, Kathrin U.); Gruber, WC (Gruber, William C.)

来源出版物：NEW ENGLAND JOURNAL OF MEDICINE

出版商：MASSACHUSETTS MEDICAL SOC

ISSN: 0028-4793

影响因子（2021）：176.082

收录情况：SCIE

5

Dexamethasone in Hospitalized Patients with Covid-19

作者：Horby, P (Horby, Peter); Lim, WS (Lim, Wei Shen); Emberson, JR (Emberson, Jonathan R.); Mafham, M (Mafham, Marion); Bell, JL (Bell, Jennifer L.); Linsell, L (Linsell, Louise); Staplin, N (Staplin, Natalie); Brightling, C (Brightling, Christopher); Ustianowski, A (Ustianowski, Andrew); Elmahi, E (Elmahi, Einas); Prudon, B (Prudon, Benjamin); Green, C (Green, Christopher); Felton, T (Felton, Timothy); Chadwick, D (Chadwick, David); Rege, K (Rege, Kanchan); Fegan, C (Fegan, Christopher); Chappell, LC (Chappell, Lucy C.); Faust, SN (Faust, Saul N.); Jaki, T (Jaki, Thomas); Jeffery, K (Jeffery, Katie); Montgomery, A (Montgomery, Alan); Rowan, K (Rowan, Kathryn); Juszczak, E (Juszczak, Edmund); Baillie, JK (Baillie, J. Kenneth); Haynes, R (Haynes, Richard); Landray, MJ (Landray, Martin J.)

团体作者：RECOVERY Collaborative Grp

摘要：BACKGROUND

Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.

METHODS

In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. Here, we report the final results of this assessment.

RESULTS

A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001). The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization. In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.92 to 1.55).

CONCLUSIONS

In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.

来源出版物：NEW ENGLAND JOURNAL OF MEDICINE

出版商：MASSACHUSETTS MEDICAL SOC

ISSN: 0028-4793

影响因子（2021）：176.082

收录情况：SCIE

ESI临床医学高被引论文来源出版物Top10

利用Web of Science数据库平台对2022年11月ESI临床医学领域高被引论文（被引频次排名前20000篇）来源出版物进行统计，按照发表论文数排序得到排名前十的出版物信息如下图所示。

ESI临床医学热点论文来源出版物Top10

利用Web of Science数据库平台对2022年11月ESI临床医学领域热点论文来源出版物进行统计，按照发表论文数排序得到排名前十的出版物信息如下图所示。

ESI 知识点

01

什么是ESI

ESI（Essential Science Indicators，基本科学指标）是美国科技信息研究所于2001年推出的一个在汇集和分析SCIE/SSCI所收录的学术论文及其所引用的参考文献的基础上建立起来的分析型数据库，是目前被学术界认可的衡量科学研究绩效、跟踪科学发展趋势的分析评价工具。

02

ESI排名

ESI按照22个学科领域，分别对全球的国家和地区、研究机构、论文以及个人近十年的总被引频次进行滚动统计并排序，统计结果每2个月公布一次。其中ESI机构排名指的是 根据总被引频次的高低，分别对22个学科领域排名全球前1%的机构进行排序。

03

高水平论文

高水平论文（Top Paper）： 高被引论文和热点论文取并集后的论文集合。

04

ESI 22个学科

ESI22个学科领域详见下表。

注：加*的领域是我校已进入全球前百分之一的学科（其中工程学已进入全球前千分之一）

往期链接

【学科前瞻No.15】工程学高水平论文快报2021年11月

【学科前瞻No.14】地球科学高水平论文快报2021年5月

【学科前瞻No.13】ESI临床医学、环境科学与生态学、社会科学总论高水平论文快报2021年3月

【学科前瞻No.12】ESI地球科学、数学、物理学高水平论文快报2020年9月

【学科前瞻No.11】化学高水平论文快报2020年7月

图文 | 刘雯

编辑 | 刘雯

责编 | 汤亚南